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egeneration of Human Infarcted Heart
uscle by Intracoronary Autologous Bone Marrow
ell Transplantation in Chronic Coronary Artery Disease
he IACT Study
odo E. Strauer, MD,* Michael Brehm, MD,* Tobias Zeus, MD,* Thomas Bartsch, MD,*
hristina Schannwell, MD,* Christine Antke, MD,† Rüdiger V. Sorg, PHD,‡ Gesine Kögler, PHD,‡
eter Wernet, MD,‡ Hans-Wilhelm Müller, MD,† Matthias Köstering, MD*
üsseldorf, Germany
OBJECTIVES Stem cell therapy may be useful in chronic myocardial infarction (MI); this is conceivable, but
not yet demonstrated in humans.
BACKGROUND After acute MI, bone marrow-derived cells improve cardiac function.
METHODS We treated 18 consecutive patients with chronic MI (5 months to 8.5 years old) by the
intracoronary transplantation of autologous bone marrow mononuclear cells and compared
them with a representative control group without cell therapy.
RESULTS After three months, in the transplantation group, infarct size was reduced by 30% and global
left ventricular ejection fraction (15%) and infarction wall movement velocity (57%)
increased significantly, whereas in the control group no significant changes were observed in
infarct size, left ventricular ejection fraction, or wall movement velocity of infarcted area.
Percutaneous transluminal coronary angioplasty alone had no effect on left ventricular function.
After bone marrow cell transplantation, there was an improvement of maximum oxygen
uptake (VO2max, 11%) and of regional
18F-fluor-desoxy-glucose uptake into infarct tissue
(15%).
CONCLUSIONS These results demonstrate that functional and metabolic regeneration of infarcted and
chronically avital tissue can be realized in humans by bone marrow mononuclear cell
transplantation. (J Am Coll Cardiol 2005;46:1651–8) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.069Cardiology Foundation
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aardiac performance after myocardial infarction (MI) is
ompromised by ventricular remodeling, which represents a
ajor cause of late infarct-related chronic heart failure and
eath (1,2). Although conventional drug therapy (e.g., with
eta-receptor blockers and/or angiotensin-converting en-
yme inhibitors) may delay remodeling, there is no basic
See page 1659
herapeutic regimen available for preventing or even revers-
ng this process. By the use of interventional therapeutics
percutaneous transluminal coronary angioplasty [PTCA],
tent), recanalization of the occluded infarct-related artery is
ossible, thereby improving or normalizing coronary blood
ow. However, despite sufficient reperfusion of infarcted
issue, the viability of the infarcted myocardium cannot, or
an only insufficiently, be improved in most of these patients
3). Therefore, catheter-based therapy of acute MI is useful
or vascular recanalization, but the second and crucial step,
From the *Department of Internal Medicine, Division of Cardiology, Pneumology
nd Angiology; †Department of Nuclear Medicine; and ‡Institute for Transplanta-
ion Diagnostics and Cell Therapeutics, Heinrich-Heine-University, Düsseldorf,
ermany.i
Manuscript received October 31, 2004; revised manuscript received December 13,
004, accepted January 25, 2005.he regeneration of necrotic heart muscle, is not realized by
his vascular procedure alone.
Experimental (4) and clinical (5,6) studies have shown
ecently for the first time that bone marrow mononuclear
ells (BMCs) may regenerate damaged myocardium in acute
I in humans. Because the regenerative potential of bone
arrow-derived cells ought also to be expected to exist in
hronically ischemic heart disease as well (7–12), we have
ssembled in an ongoing clinical investigation 18 patients
ith chronic MI to prove this new therapeutic possibility.
ETHODS
tudy population. All 18 patients (49  11 years) were
en and were recruited consecutively from January 2003
ntil March 2004. They had had transmural MI 27  31
onths before, at which point all infarcts had been treated
cutely by PTCA and/or stent implantation (Table 1, Fig. 1).
The inclusion criteria were age 70 years, one-vessel
isease with an open infarct-related artery at the time of
tem cell therapy, sinus rhythm, a clear-cut demarcation of
he ventriculographic infarct area, and no coronary bypass
urgery. General exclusion criteria were severe comorbidity
nd alcohol or drug dependency. Although chronically
nfarcted myocardium usually does not regenerate sponta-
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Regeneration of Infarction by BMCs in Chronic CAD November 1, 2005:1651–8eously, for comparison a control group, parallel to the
ecruitment of the stem cell transplantation group (Tx
roup), was recruited and analyzed, meeting the same
nclusion criteria as the stem-cell group. The recruitment of
atients was performed according to a randomization pro-
edure in which all patients of the entire chronic infarction
roup were distributed to the treatment group, where they
greed with all the therapeutic regimen. Alternatively, all
atients of the chronic infarction group who refused the
herapeutic regimen (bone marrow puncture and aspiration,
ntracoronary cell transplantation, and another cardiac cath-
terization) were allocated to the control group. All medi-
ations with angiotensin-converting enzyme inhibitors and
ith beta receptor blockers were maintained constant dur-
ng the study period.
The cell-treated patients had stable ventricular dynamics
or infarct size, ejection fraction, and wall movement velocity
f infarcted area at least 9  6 months before cell transplan-
ation. Infarct size at the time of cell therapy showed an
mount of 27 8% of the circumference of the left ventricle
LV), determined by ventriculography.
reparation of BMCs. One day before cell therapy, bone
arrow was taken (80 ml from the iliac crest) and mono-
Table 1. Demographic Data of Intracoronary B
and Control Group
Characteristics
No. of patients
Age, yrs
Transmural myocardial infarction, months before Tx
Coronary angiography
LAD/LCX/RCA as affected vessel
No. of patients with stent implantation
Risk factors
Diabetes mellitus, %
Positive family history, %
Smoker and ex-smoker, %
Hyperlipoproteinemia, %
Medication
Beta-blocker, %
Angiotensin-converting enzyme inhibitor, %
Statin, %
Laboratory parameters
CPK, U/l
Bone marrow mononuclear cells, n (106)
Values are mean  SD or number of patients.
Abbreviations and Acronyms
BMC  bone marrow mononuclear cell
CPK  creatine phosphokinase
ECG  electrocardiogram
LV  left ventricular
MI  myocardial infarction
PET  positron emission tomography
PTCA  percutaneous transluminal coronary
angioplasty
Tx group  transplantation groupCPK  creatine phosphokinase; LAD  left anterior descendi
RCA  right coronary artery; Tx  intracoronary bone marrow suclear cells were isolated and identified including CD34-
ositive cells, AC133-positive cells and CD45/CD14 neg-
tive cells (6). The cells were isolated under good
anufacturing practice conditions by Ficoll density separa-
ion on Lymphocyte Separation Medium (Bio Whittaker,
alkersville, Maryland), before the residual erythrocytes
ere lysed with H2O. For overnight cultivation, 1  10
6
MCs/ml were placed in Teflon bags (Vuelife, Cell Genix,
aithersburg, Maryland) and cultivated in X-Vivo 15 Me-
ium (Bio Whittaker) supplemented with 2% heat-
nactivated autologous plasma. The next day, BMCs were
arvested and washed three times with heparinized saline
efore final resuspension in heparinized saline. Viability was
3  3%. Heparinization and filtration (cell strainer,
ALCON) was carried out to prevent cell clotting and
icroembolization during intracoronary transplantation.
hese cells were used for therapy. All microbiologic tests of
he clinically used cell preparations proved negative. All
atients received extensive information about the procedure,
hich was approved by the ethical committee of our
niversity, and all gave written informed consent.
dministration of BMCs. Following assessment of base-
ine examinations (coronary angiography, left ventricu-
ography, spiroergometry, 99mTc-tetrofosmin single-
hoton emission computed tomography (SPECT) and
8F-fluor-deoxy-glucose (18F-FDG) positron emission
omography (PET), cell transplantation was performed
ia the intracoronary administration route (6,13) using
our to six fractional infusions parallel to balloon inflation
ver 2 to 4 min of 3 to 5 ml of cell suspension, each
ontaining 15 to 22  106 mononuclear cells. All cells were
nfused directly into the infarcted zone through the infarct-
elated artery via an angioplasty balloon catheter, which was
nflated at a low pressure (2 to 4 atm) and was located within
Marrow Stem Cell Transplantation Group
Tx Group Control Group p
18 18
49  11 52  10 NS
27  31 30  34 NS
16/0/2 10/3/5
16 17 NS
16 11 NS
44 33 NS
67 56 NS
89 94 NS
94 89 NS
94 89 NS
94 100 NS
1,504  979 1,489  952 NS
90oneng coronary artery; LCX  left circumflex coronary artery;
tem cell transplantation.
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November 1, 2005:1651–8 Regeneration of Infarction by BMCs in Chronic CADhe previously stented coronary segments. This prevented
ackflow of cells and produced stop flow beyond the site of
alloon inflation to facilitate high-pressure infiltration of
ells into the infarcted zone. Prolonged contact time for
ellular migration was also enabled. Three months after
atheter-guided cell transplantation, all functional tests were
epeated, including coronary angiography and left ventricu-
ography. There were no procedural or cell-induced com-
lications, and there were no side effects in any patient.
piroergometry. Aerobic exercise capacity was examined
efore (10 days) intracoronary cell transplantation and
hree months later during follow-up. All patients (n  18)
ere subjected to initial bicycle spiroergometry to assess
heir functional fitness and to determine the limit of safe
ntensity of exercise. We chose a protocol with an intensi-
ed workload up to the symptom-limited maximum (basic
oad of 50 W, intensification at 25 W, 2-min duration of
ach workload step). We determined the anaerobic thresh-
ld for prescribing a suitable load intensity. During the
hole spiroergometry, monitoring by a 12-lead electrocar-
iogram (ECG) was carried out. The exercise capacity was
ssessed on the basis of maximum load levels expressed in
atts (Wmax) and maximum peak oxygen uptake (VO2max).
oronary angiography and left ventriculography. Coro-
ary angiography and biplane left ventriculography were
erformed 9 6 months before cell transplantation and also
second time, within 10 days, immediately before cell
herapy. The therapeutic follow-up was three months after
he treatment. Thus, stable baseline conditions were docu-
ented (coronary vessel involvement, ventricular function,
igure 1. Diagrammatic representation of the algorithm of intracoronary ste
he infarcts occurred 27  31 months before Tx. All infarct patients wer
tent implantation. 9  6 months before (investigation 1) coronary angiogr
as present, re-PTCA was made. Investigation 2 embraces all patients for
n open infarct-related artery were included in both groups. Patients who a
nd Tx by the intracoronary administration route and had altogether five
atients who were not eligible for Tx (disagreement with bone marrow
epresents all follow-up measurements 3 months after Tx (Tx patients) ornd geometry). Cardiac function was evaluated by left fentricular (LV) ejection fraction and by auxotonic myocar-
ial contractility index, evaluated by the wall movement
elocity of the infarcted area. The infarct size was calculated
ccording to the method of Sheehan (14) by plotting five
xes perpendicular to the long axis of the heart in the main
kinetic or dyskinetic segment of the ventricular wall.
ystolic and diastolic lengths were then measured by two
ndependent observers, and the mean difference was divided
y the systolic duration in seconds.
uantification of coronary stenosis (restenosis). Cineco-
onarangiograms were obtained during stem cell transplan-
ation and at three months thereafter according to standard
cquisition guidelines. The angiograms were evaluated by
wo independent observers and quantitative analysis was
erformed (15). Standard morphologic criteria were used to
haracterize the complexity of baseline lesions. The user-
efined reference diameter proximal to the stenosis and the
inimal luminal diameter within the culprit of the stenosis
ere used to calculate the percentage of stenosis. A value of
mm was assigned for the minimal luminal diameter in case
f total occlusion at baseline or follow-up. Restenosis was
efined as 50% stenosis of the initial target lesion at
ollow-up. Calculations of restenosis were performed in
oth groups, with and without stem cell therapy, in the
ame way, thus enabling evaluation the differential effects of
TCA-guided cell therapy and of PTCA effects alone.
entricular function after PTCA in the control group.
or the evaluation of a potential effect on the PTCA
ntervention itself on LV function, all patients in the control
roup were analyzed with regard to infarct size, ejection
l therapy (Tx) in chronic ischemic heart disease after myocardial infarction.
ted with percutaneous transluminal coronary angioplasty (PTCA) or with
(including quantitative left ventriuclography) was performed. If re-stenosis
valuation of coronary morphology after PTCA/stent. Only patients with
to Tx received within 10 days after investigation 2 bone marrow punctures
sive investigations, including two for therapeutic reasons (nos. 0 and 1).
ure and with subsequent Tx) served as a control group. Investigation 3
investigation 2 for control group patients.m cel
e trea
aphy
the e
greed
invaraction, and infarction wall movement velocity.
Table 2. Single Values of Intracoronary Bone Marrow Stem Cell Transplantation Group
Patient
Number
Area of Infarction, %* LV Ejection Fraction, %* Infarction Wall Movement Velocity, cm/s*
Investigation 1
9  6 Mo
Before Tx
Investigation 2
<10 Days
Before Tx
Investigation 3
3 Mo
After Tx
Investigation 1
9  6 Mo
Before Tx
Investigation 2
<10 Days
Before Tx
Investigation 3
3 Mo
After Tx
Investigation 1
9  6 Mo
Before Tx
Investigation 2
<10 Days
Before Tx
Investigation 3
3 Mo
After Tx
1 26 26 22 56 55 60 0.88 0.77 0.82
2 28 29 26 45 43 49 2.06 1.88 2.13
3 16 16 5 64 65 71 1.45 1.50 2.10
4 27 25 14 48 50 65 1.20 1.25 2.88
5 16 14 11 66 69 71 2.25 2.77 3.75
6 16 13 6 64 66 73 1.50 1.77 2.55
7 15 18 11 57 55 63 2.78 2.65 3.13
8 28 28 20 43 44 49 3.15 3.25 4.25
9 27 27 11 46 46 64 1.61 1.65 3.30
10 20 17 14 56 58 62 2.21 2.45 3.13
11 28 25 17 42 38 52 1.91 1.88 3.00
12 33 28 21 44 47 54 2.28 2.62 3.50
13 39 37 27 50 51 59 1.25 2.50 4.90
14 29 33 27 62 62 61 1.20 1.33 2.70
15 37 37 31 48 43 53 1.83 1.56 2.50
16 29 29 24 53 54 58 1.25 1.06 3.06
17 41 35 48 55 1.66 3.00
18 35 25 45 53 0.94 1.94
Mean 26 27 19 53 52 60 1.80 1.86 2.92
SD 7 8 9 8 9 7 0.63 0.70 0.91
*Calculated from left ventriculography.
LV  left ventricular; Mo  Months; other abbreviations as in Table 1.
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November 1, 2005:1651–8 Regeneration of Infarction by BMCs in Chronic CADuclear cardiologic investigations (PET and SPECT).
8F-FDG-positron emission tomography (18F-FDG PET)
as performed with a Scanditronix SCX 4096 WB-Scanner
FWHM  6 mm transaxial, axial field of view  4.6 cm).
atients received an oral glucose load of 1 g/kg body weight
0  30 min before the intravenous application of 18F-
DG (380  60 MBq). The 18F-FDG was administered at
he time of decrease of blood glucose level 130 mg/dl. An
nitial transmission scan was obtained using a 68Ga-filled
in source to correct the subsequent emission scans for
ttenuation. The data acquisition was started 45 min after
dministration of FDG. Image data were recorded with a
56  256 matrix in 3 consecutive bed positions over 15
in per position. The data were reconstructed back-
rojected with a Hanning filter (5 mm).
9mTc-tetrofosmin SPECT. Sixty minutes after intrave-
ous injection of 600  140 MBq of the perfusion-marker
9mTc-tetrofosmin under a “rest” condition, the images
ere obtained using a SPECT scanner with double-head
etector (PRISM 2000, Marconi/Phillips), a low-energy,
igh-resolution collimator, and a 128  128 matrix. Image
ata were collected over 360° at 3° every 30 s. The images
ere reconstructed backprojected with a low-pass filter
order 12, cutoff 0.2).
ET and SPECT evaluation. Normalized values for
DG uptake and perfusion were calculated by comparing
egional with maximum tracer uptake on the reconstructed
mages. We performed a regional analysis of glucose me-
abolism and perfusion using a set of standardized, individ-
ally adjusted circular regions of interest (diameter 18.06
m, surface 256 mm2). The reconstructed metabolic and
erfusion images were realigned for each patient (MPI-
ool, version 3.0; Advanced Tomo Vision, Erftstadt, Ger-
any) and were resliced according to cardiac axis (short-axis
nd horizontal and vertical long-axis views). The regions
ere positioned immediately neighboring, with no overlap,
ccording to an overlay of the co-registrated metabolic and
erfusion images. The regions covered the infarct lesion as
ell as normal myocardium. In this way, we generated
emplates of regions for each patient, which could be used
or the evaluation of metabolism and perfusion, before and
fter BMC transplantation without further modification.
ccording to Segall et al. (16), regions with a normalized
DG uptake 50% were rated as transmural scar and
egions with an uptake of 50% to 60% as non-transmural
car.
able 3. Cardiac Parameters in the Transplantation Group and in
Area of Infarction, % LV
Control
Group Tx Group p Value*
Control
Group
nvestigation 1 25  9 26  7 0.99 53  10
nvestigation 2 27  9 27  8 0.83 51  10
nvestigation 3 26  9 19  9 0.02 52  10Analysis of variance.
Abbreviations as in Table 1.Further analysis was restricted to regions with FDG
ptake 60% in the PET scans, pursuant to our intention
o focus on the effects of BMC transplantation on scar
issue.
afety parameters. To assess any inflammatory response
nd myocardial reaction after cell therapy, white blood cell
ount, the serum levels of C-reactive protein (CRP) and of
reatine phosphokinase (CPK) were determined immedi-
tely before as well as after treatment. Additional analysis was
one directly after transplantation and three months later:
CG at rest, 24-h Holter ECG, and echocardiography.
tatistical analysis. All data are presented as mean  SD.
tatistical significance was accepted when p  0.05. Intra-
ndividual comparison of variables of investigation 1 (9  6
onths before cell transplantation for Tx group, 9  5
onths before investigation 2 for control patients) and
nvestigation 2 (10 days before cell transplantation for Tx
roup, no transplantation for control patients) and of
ariables of investigation 2 and follow-up investigation 3 (3
onths after cell therapy for Tx group, 8  5 months after
nvestigation 2 for control patients) was performed using
ilcoxon rank-sum test. The missing values (Table 2) were
mitted and not calculated for statistical analysis. The
values (by analysis of variance) have been given for LV
jection fraction, area of infarction, and infarction wall
ovement velocity. Statistical analysis was performed with
PSS-Windows 10.1 software.
ESULTS
hree months after intracoronary cell therapy, the infarct
ize was reduced by 30%, whereas the global LV ejection
raction increased by 15% and regional infarct wall move-
ent velocity by 57% (Tables 2 and 3). In parallel, the
linical performance improved (Table 4), as evidenced by a
igher work load demonstrated by a 11% increase in
aximum oxygen uptake (VO2max). SPECT investigation
resented enhanced tetrofosmin uptake in the infarcted
one by 5%, and PET examination showed enhanced
lucose uptake in the infarcted zone by 15%, demonstrating
egeneration of formerly avital, chronically infarcted heart
uscle (Fig. 2). An unchanged or even impaired LV
unction was not observed in any patient.
In the control group (18 patients with chronic MI, but
ithout stem cell therapy) no significant changes were
bserved in infarct size, LV ejection fraction, or wall
ntrol Group at the Three Investigation Time Points
ction Fraction, % Infarction Wall Movement Velocity, cm/s
Tx Group p Value*
Control
Group Tx Group p Value*
53  8 0.87 1.95  0.66 1.80  0.63 0.57
52  9 1.00 1.88  0.76 1.86  0.70 0.94
60  7 0.02 1.91  0.79 2.92  0.91 0.001Co
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Regeneration of Infarction by BMCs in Chronic CAD November 1, 2005:1651–8ovement velocity of the infarcted area (Figs. 3A to 3C).
lectrocardiogram at rest and on exercise and 24-h Holter
CG revealed no rhythm disturbances at any time point.
nly 1 patient (from 18 cell-treated patients, 6%) developed
elevant restenosis due to quantitative angiographic criteria.
he restenosis could be treated adequately by stent implan-
ation. The other 17 patients showed good patency rates
ithout restenosis after PCI and cell transplantation. They
lso revealed no alterations in LV function 8  5 months
fter PTCA.
There was no inflammatory response or myocardial reac-
ion (white blood cell count, CRP, CPK) after cell therapy,
espite a moderate increase in CRP (before cell transplan-
ation 0.58  0.48 mg/dl, after cell transplantation 1.07 
.73 U/l, p  0.002), which is usual after bone marrow
uncture and/or cardiac catheterization.
ISCUSSION
he results of these investigations demonstrate, for the first
ime, that the intracoronary transplantation of autologous
one marrow mononuclear cells may reduce infarct size and
mprove LV function as well as myocardial glucose uptake
n chronic ischemic heart disease attributable to chronic MI
5 months to 8.5 years old). Infarct size decreased in all
atients and cardiac performance (ejection fraction, wall
ovement velocity of infarcted area, maximum oxygen
ptake, and exercise tolerance) and myocardial metabolism
FDG-PET) improved, all being between 11% and 57%.
urthermore, it is noteworthy that there were no compli-
ations immediately or three months after cell transplanta-
ion, especially that there was no cardiac arrhythmia and no
igns of cardiac or systemic inflammation were present.
igure 2. Representative illustration of 18F-FDG-positron emission tomo
Table 4. Positron Emission Tomography and
Therapy in Chronically Infarcted Myocardium
18F-FDG-Positron Emi
Tomography
FDG Uptake, % Dif
Investigation 1 none
Investigation 2 43.8  8.0 Investigation 3 50.5  11.6
p (Wilcoxon test) 0.012
18F-FDG  18F-fluor-deoxy-glucose; VO2max  maximumransversal (left) and longitudinal (right projection) in a 30-year-old male pati
lucose uptake (below) within the infarcted area of the formerly completely aviThe effects of stem cell transplantation on infarct size,
ardiac function, and contractility demonstrate significant im-
rovement of these three parameters in the therapy group
before and after stem cell therapy) as well as in the comparison
etween the stem cell therapy group and the control group,
hus giving evidence for a beneficial therapeutic effect of stem
ell therapy on cardiac performance in chronic MI.
Patients in both the stem-cell group and the control
roup were recruited in parallel to each other and consec-
tively between January 2003 and March 2004. They all
n  36) fulfilled the same inclusion criteria. Thus,
epresentative patient characteristics were present for the
tem cell group (n  18) and the control group (n  18)
s well as in comparing both of them. Moreover, two
ubsequent investigations before stem cell transplantation
ave been performed for each patient: investigation 1 and
demonstrated the stability of LV dynamics before cell
herapy (9 months respectively 10 days before transplanta-
ion) and investigation 3 compared the effects of stem cell
herapy with the control group. The stable hemodynamics
uring the preceding 9 6 months before stem-cell therapy
nd the stable hemodynamics within the control group at all
hree points of investigation underline the significant alter-
tions of the left ventriculography-derived parameters in-
estigated after stem cell transpantation.
The regenerative potential of bone-marrow–derived stem
ells may be explained by any of four mechanisms: 1) direct
ell differentiation from mononuclear cells to cardiac myo-
ytes (17), 2) cytokine-induced growing and increase of
esidual viable myocytes, especially within the border zone
f the infarcted area (18), 3) stimulation of intrinsic myo-
ardial stem cells (endogenous stem cells) (19,20), and 4)
y (PET) before (above) and 3 months after (below) cell therapy in the
ergometry Before and After Stem Cell
VO2max, Spiroergometry
e in % ml/min Difference in %
none
5 1,602  533   111,776  523
0.0001
uptake.graphSpiro
ssion
ferenc
 1ent with an 8-month-old anteroapical infarction. Note the restoration of
tal anteroapical myocardium.
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November 1, 2005:1651–8 Regeneration of Infarction by BMCs in Chronic CADnduction of cell fusion between transplanted bone marrow
ells and resident myocytes (21–24).
Transdifferentiation has been described by previous in-
estigators (4); however, it has been questioned by recent
igure 3. Illustration of the mean values of (A) area of infarction, (B)
jection fraction, and (C) infarction wall movement velocity, determined by
uantitative left ventriculography in both groups (control group vs. trans-
lantation [Tx] group) at the point of time: investigations 1, 2, and 3.
omparision of both groups with chronically infarcted myocardium (conrol
roup vs. Tx group), n  18 patients. Investigation 1 was 9  6 months
efore cell transplantation (controls: 9  5 months before percutaneous
ransluminal coronary angioplasty [PTCA]); investigation 2 within 10 days
efore cell tranplantation (controls: at the time point of PTCA) and
nvestigation 3 was three months after cell transplantation (controls: 8  5
onths after PTCA). Note the significant decrease of infarct size and the
ncrease in ejection fraction and in contractility (infarction wall movement
elocity) 3 months after cell therapy in comparison with the control group.
p  not significant (investigation 2 vs. investigation 3); #p  0.001
investigation 2 vs. investigation 3).xperimental studies (25). The influence of cytokines has rhown to restore coronary blood vessels and muscle cells
fter experimental myocardial infarction. This regeneration
f blood vessels and muscle cells is most pronounced in the
order zone of ischemic and/or infarcted tissue (26), dem-
nstrating an enhancement of mitotic cells and cell cycles up
our-fold, when compared to areas remote from the necrotic
yocardium. Moreover, mononuclear bone marrow stem
ells contain a lot of cytokines (VEGF, insulin-like growth
actor, platelet-derived growth factor, and so on), thereby
timulating residual normal myocytes for regeneration and
roliferation and instrinsic myocardial stem cells (endoge-
ous stem cells) for cell regeneration and for cell fusion
27–31).
Mitotic indexes are three to four times more frequent
ithin the border zone of myocardial necrosis when com-
ared with non-injured heart muscle (26). Moreover, 20%
o 40% of intracoronarily transplanted bone-marrow–
erived stem cells may be accumulated within the border
one of MI. There were no signs of apparent microcircula-
ion disturbances because all patients had Thrombolysis In
yocardial Infarction flow grade 3. Thus, it is conceivable
hat in MI the border zone represents the optimum “niche”
or exogenously transplanted stem cells, stimulating mitosis
ates and heart muscle regeneration, preferably originating
n and expanding from these areas. Cell fusion may also
ontribute to heart muscle regeneration, which takes its
rigin from the border zone, expanding gradually to the
ecrotic core of the infarcted area.
Our study cannot determine which cell-biologic and
olecular mechanims are responsible for heart muscle repair
r which of the studied factors may play the predominant
ole. However, the final functional outcome of this cell therapy
emonstrates three main target effects: improvement in
uscle function (pumping ability and contractility), myo-
ardial perfusion (SPECT), and myocardial glucose metab-
lism (PET), thus giving evidence that heart muscle repair
ust have taken place by this intracoronary bone marrow
ell transplantation procedure.
The clinical significance of this novel therapeutic ap-
roach may embrace a large number of patients with chronic
oronary artery disease, preferably after previous or long-
tanding MI. It is conceivable that remodeling after infarc-
ion may be ameliorated or even stopped by this procedure.
hus, cell therapy may represent a new option of basic and
ausal therapy in chronic infarcted myocardium. It is an
pen question whether variations of the amount and kind of
one marrow cells, the administration technique, and the
ransplantation procedure itself, by enhanced environment
nd improvement of the angiogenic micromilieu, can fur-
her improve the milieu-dependent differentiation or regen-
ration of bone marrow cells in chronic infarcted heart
isease. Therefore, our clinical results represent a stable basis
o proceed to the next necessary step: to a larger prospective
andomized study.
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